Publications

Search our bibliography using the filters on the right-hand side.

Displaying 51 through 100 of 341 publications.

Barrett A, Hahn-Pedersen J, Kragh N, Evans E, Gnanasakthy A. Patient-reported outcome measures in atopic dermatitis and chronic hand eczema in adults. Poster presented at the ISPOR 2019 European Conference; November 4, 2019. Copenhagen, Denmark. [abstract] Value Health. 2019 Dec; 22(S3).

Simpson E, Eckert L, Gadkari A, Mallya UG, Yang M, Nelson L, Brown M, Reaney M, Mahajan P, Guillemin I, Boguniewicz M, Pariser D. Validation of the Atopic Dermatitis Control Tool (ADCT©) using a longitudinal survey of biologic-treated patients with atopic dermatitis. BMC Dermatology. 2019 Nov 6;19(1):15. doi: 10.1186/s12895-019-0095-3

Augustin M, Feldman S, Poulos C, Gilloteau I, Mange B, Boeri M, Boehm K, Melzer N, Gutknecht M. Patient preferences for treatment of moderate to severe psoriasis: a discrete choice experiment study in Germany. Poster presented at the 28th European Academy of Dermatology and Venereology (EADV) Congress; October 11, 2019. Madrid, Spain.

Carrico J, Jia X, Zhao Y, Zhang J, Brodtkorb T, Mendelsohn A, Wu J, Feldman S, Armstrong A. Cost-effectiveness and budget impact of tildrakizumab for the treatment of moderate to severe plaque psoriasis using 2019 drug costs. Poster presented at the 2019 AMCP NEXUS; October 29, 2019. National Harbor, MD. [abstract] J Manag Care Spec Pharm. 2019 Oct; 25(10-a Suppl):S79. doi: 10.18553/jmcp.2019.25.10-a.s1

Barrett A, Hahn-Pedersen J, Kragh N, Evans E, Gnanasakthy A. Patient-reported outcome measures in atopic dermatitis and chronic hand eczema in adults. Patient. 2019 Oct;12(5):445-9. doi: 10.1007/s40271-019-00373-y

Nelson LM, DiBenedetti D, Pariser DM, Glaser DA, Hebert AA, Hofland H, Drew J, Ingolia D, Gillard KK, Fehnel S. Development and validation of the axillary sweating daily diary: a patient-reported outcome measure to assess axillary sweating severity. J Patient Rep Outcomes. 2019 Sep 5;3(1):59. doi: 10.1186/s41687-019-0148-8

Gutierrez L, Booth H, Dedman D, Crellin E, Kaye JA, Franzoni C, Arana A, Schmitt-Egenolf M, Sundstrom A, Bystrom C. Case validation of cutaneous lymphoma to minimize protopathic bias. Poster presented at the 35th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 27, 2019. Philadelphia, PA. [abstract] Pharmacoepidemiol Drug Saf. 2019 Aug 20; 28(S2):645. doi: 10.1002/pds.4864

Magrey M, Bozyczko M, Wolin D, Mordin M, McLeod L, Davenport E, Chirila C, Park Y. A pilot study to assess the feasibility of a web-based survey to examine patient-reported symptoms and satisfaction in patients with ankylosing spondylitis receiving secukinumab. Drugs Real World Outcomes. 2019 Jun;6(2):83-91. doi: 10.1007/S40801-019-0154-4

Houghton K, Stull D, Germino B. A novel analytic modeling approach for linking real-world and clinical trial data. Poster presented at the 2019 ISPOR 24th Annual International Meeting; May 22, 2019. New Orleans, LA.

Carrico J, Jia X, Zhao Y, Zhang J, Brodtkorb TH, Mendelsohn AB, Lowry S, Wu JJ, Feldman SR, Armstrong AW. Budget-impact and cost-effectiveness of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis from a US health plan perspective. Poster presented at the 2019 ISPOR 24th Annual International Meeting; May 21, 2019. New Orleans, LA.

Feldman S, Poulos C, Gilloteau I, Mange B, Germino B, Boehm K, Gutknecht M, Augustin M. Patient preferences for treatment of moderate-to-severe psoriasis: a U.S. discrete-choice experiment survey. Poster presented at the 2019 American Academy of Dermatology (AAD) Annual Meeting; March 2, 2019. Washington, DC.

Jia X, Zhao Y, Carrico J, Brodtkorb TH, Mendelsohn A, Lowry S, Feldman S, Wu JJ, Armstrong A. Cost-effectiveness of tildrakizumab in U.S. patients with moderate-to-severe plaque psoriasis. Poster presented at the 2019 American Academy of Dermatology (AAD) Annual Meeting; March 1, 2019. Washington, DC. Previously presented at the 2018 Academy of Managed Care Pharmacy (AMCP) Nexus Conference.

Jia X, Zhao Y, Carrico J, Brodtkorb TH, Mendelsohn A, Lowry S, Feldman S, Armstrong A, Wu JJ. Comparative cost per time in response for tildrakizumab in U.S. patients with moderate-to-severe plaque psoriasis. Poster presented at the 2019 American Academy of Dermatology (AAD) Annual Meeting; March 1, 2019. Washington, DC. Previously presented at the 2018 Academy of Managed Care Pharmacy (AMCP) Nexus Conference.

Augustin M, Mcbride D, Gilloteau I, O'Neill C, Neidhardt K, Graham CN. Cost-effectiveness of secukinumab as first biologic treatment, compared with other biologics, for moderate to severe psoriasis in Germany. J Eur Acad Dermatol Venereol. 2018 Dec;32(12):2191-9. doi: 10.1111/jdv.15047

Warren RB, Halliday A, Graham CN, Gilloteau I, Miles L, Mcbride D. Secukinumab significantly reduces psoriasis-related work impairment and indirect costs compared with ustekinumab and etanercept in the United Kingdom. J Eur Acad Dermatol Venereol. 2018 Dec;32(12):2178-84. doi: 10.1111/jdv.15094

Lacour JP, Khemis A, Giordano-Labadie F, Martin Lu, Staumont-Salle D, Hacard F, Tian H, McBride D, Hollis K, Hunter S, Martin L, Lamirand A, Le Guen S, Balp MM, Berard F. The burden of chronic spontaneous urticaria: unsatisfactory treatment and healthcare resource utilization in France (the ASSURE-CSU study). Eur J Dermatol. 2018 Dec 1. doi: 10.1684/ejd.2018.3446

Maurer M, Houghton K, Costa C, Dabove F, Ensina LF, Gimenez-Arnau A, Guillet G, Konstantinou GN, Labrador-Horrillo M, Lapeere H, Meshkova R, Pastorello E, Velasquez-Lopera M, Tamayo Quijano LM, Vestergaard C, Chapman-Rothe N. Differences in chronic spontaneous urticaria between Europe and Central/South America: results of the multi-center real world AWARE study. World Allergy Organ J. 2018 Nov 16;11(32). doi: 10.1186/s40413-018-0216-1

Poulos C, Feldman SR, Gilloteau I, Boeri M, Guana A, Germino B, Boehm K, Gutknecht M, Augustin M. The most influential drivers of psoriasis patients' treatment choice: a discrete choice experiment survey in the US. Poster presented at the 2018 ISPOR 21st Annual European Congress; November 12, 2018. Barcelona, Spain.

Miles L, Purser M. A global review of the quality of life impact of atopic dermatitis in children. Poster presented at the 2018 ISPOR 21st Annual European Congress; November 12, 2018. Barcelona, Spain.

Bianculli PM, Salibe M, Peirano I, Gilloteau I, Graham C. Secukinumab as first biologic treatment: a cost per responder analysis compared with licensed biologics, for moderate to severe psoriasis in Argentina. Poster presented at the 2018 ISPOR 21st Annual European Congress; November 12, 2018. Barcelona, Spain.

Suzuki C, Lopes N, Gilloteau I, Graham C. Cost per responder of secukinumab compared to other biologics in moderate-to-severe plaque psoriasis from the private payer perspective in Brazil. Poster presented at the 2018 ISPOR 21st Annual European Congress; November 12, 2018. Barcelona, Spain.

Kooli A, Graham C, Scheuer N, Gilloteau I, Miles L, Sherif B, Mcbride D. Secukinumab significantly reduces psoriasis-related work impairment and indirect costs compared to ustekinumab and etanercept in Morocco. Poster presented at the 2018 ISPOR 21st Annual European Congress; November 12, 2018. Barcelona, Spain.

Kooli A, Graham C, Scheuer N, Gilloteau I, Miles L, Sherif B, Mcbride D. Secukinumab significantly reduces psoriasis-related work impairment and indirect costs compared to ustekinumab and etanercept in Tunisia. Poster presented at the 2018 ISPOR 21st Annual European Congress; November 12, 2018. Barcelona, Spain.

Igarashi A, Igarashi AS, Graham CN, Gilloteau I, Tani Y. Evaluating the cost-effectiveness of secukinumab in moderate to severe psoriasis: a Japanese perspective. J Med Econ. 2018 Oct 26;22(1):7-15. doi: 10.1080/13696998.2018.1532905.

Carrico J, Zhao Y, Jia X, Brodtkorb TH, Mendelsohn A, Lowry S. Budget impact of introducing tildrakizumab for the treatment of moderate to severe plaque psoriasis in the United States. Poster presented at the 2018 AMCP NEXUS; October 24, 2018. Orlando, FL. [abstract] J Manag Care Pharm. 2018 Oct; 24(10-a):s78.

Jia X, Zhao Y, Carrico J, Brodtkorb TH, Mendelsohn A, Lowry S, Feldman S, Wu JJ, Armstrong A. Cost-effectiveness analysis of tildrakizumab in patients with moderate to severe plaque psoriasis in the United States. Poster presented at the 2018 AMCP NEXUS; October 24, 2018. Orlando, FL. [abstract] J Manag Care Pharm. 2018 Oct; 24(10-a):S78.

Jia X, Zhao Y, Carrico J, Brodtkorb TH, Mendelsohn A, Lowry S, Feldman S, Armstrong A, Wu JJ. Comparative cost per time in response for tildrakizumab and other targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis in the United States. Poster presented at the 2018 AMCP NEXUS; October 22, 2018. Orlando, FL. [abstract] J Manag Care Pharm. 2018 Oct; 24(10a):S79.

Carrigan G, Whipple S, Capra WB, Taylor MD, Lu M, Arnieri B, Brown JS, Abernethy AP, Copping R, Rothman KJ. Potential for using external control arms derived from electronic health records to replace control arms from randomized controlled trials. Poster presented at the 34th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 26, 2018. Prague, Czech Republic. [abstract] Pharmacoepidemiol Drug Saf. 2018 Aug; 27(52):357. doi: 10.1002/pds.4629

Sussman G, Abuzakouk M, Berard F, Canonica W, Oude Elberink H, Gimenez-Arnau A, Grattan C, Hollis K, Hunter S, Knulst A, Lacour JP, Lynde C, Marsland A, Mcbride D, Maurer M, Nakonechna A, Ortiz De Frutos J, Reynolds M, Sweeney C, Tian H, Weller K, Wolin D, Balp MM. Angioedema in chronic spontaneous urticaria is underdiagnosed and has a substantial impact: analyses from ASSURE-CSU. Allergy. 2018 Aug;73(8):1724-34. doi: 10.1111/all.13430

Feldman SR, Zhao Y, Gilloteau I, Graham CN, Miles L, Mcbride D, Herrera V. Higher psoriasis skin clearance is associated with lower annual indirect costs in the United States: a post hoc analysis from the CLEAR Study. J Manag Care Spec Pharm. 2018 Jul;24(7):617-22. doi: 10.18553/jmcp.2018.24.7.617

Magrey M, Bozyczko M, Wolin D, Mordin M, McLeod L, Davenport E, Park Y. Treatment experience and satisfaction in ankylosing spondylitis patients treated with secukinumab: results from a US web-based survey. Poster presented at the 2018 Annual European Congress of Rheumatology (EULAR); June 16, 2018. Amsterdam, The Netherlands.

Stull DE, Griffiths CEM, Gilloteau I, Zhao Y, Guana A, Finlay AY, Sherif B, Houghton K, Puig L. Differential effects of secukinumab vs. ustekinumab for treatment of psoriasis on quality of life, work productivity and activity impairment: a structural equation modelling analysis. Br J Dermatol. 2018 Jun;178(6):1297-307. doi: 10.1111/bjd.16366

Mease PJ, Gladman DD, Davenport EK, Zhou X, Guerette B, Teng L, Kaura S, Nash P. Improvements in work productivity with up to 104 weeks of apremilast monotherapy: results from a phase 3b, randomized, controlled study in biologic-naive subjects with active psoriatic arthritis. Poster presented at the 5th World Psoriasis & Psoriatic Arthritis Conference 2018; June 27, 2018. Stockholm, Sweden. [abstract] Acta Derm Venereol. 2018 Jun; 98(Suppl 219):14. Previously presented at the 2017 ACR/ARHP Annual Meeting. doi: 10.2340/00015555-2978

Kuiper JG, van Herk-Sukel MPP, Castellsague J, Pottegard A, Berglind IA, Dedman D, Gutierrez L, Calingaert B, Hallas J, Sundstrom A, Gallagher AM, Kaye JA, Pardo C, Rothman KJ, Perez-Gutthann S. Use of topical tacrolimus and topical pimecrolimus in four European countries: a multicentre database cohort study. Drugs Real World Outcomes. 2018 Jun;5(2):109-16. doi: 10.1007/s40801-018-0133-1

Maurer M, Houghton K, Berroa F, Ensina LF, Guillet G, Labrador M, Gimenez-Arnau AM, Marsland A, Rossi O, Velasco M, Chapman-Rothe N. Angioedema with and without wheals in patients with chronic spontaneous urticaria: findings from the worldwide prospective observational aware study. Presented at the EAACI Congress 2018; May 27, 2018. Munich, Germany.

Suzuki C, Lopes N, Tozato C, Gilloteau I, Graham CN. Cost-effectiveness of secukinumab compared to other biologics in moderate-to-severe plaque psoriasis from a Brazilian perspective. Poster presented at the 2018 ISPOR 23rd Annual International Meeting; May 22, 2018. Baltimore, MD.

Suzuki C, Lopes N, Tozato C, Gilloteau I, Graham CN. Cost per responder of secukinumab compared to other biologics in moderate-to-severe plaque psoriasis in Brazil. Poster presented at the 2018 ISPOR 23rd Annual International Meeting; May 22, 2018. Baltimore, MD. [abstract] Value Health. 2018 May; 21(Suppl 1):S240. doi: 10.1016/j.jval.2018.04.1633

Hollis K, Proctor C, Mcbride D, Balp MM, McLeod L, Hunter S, Tian H, Khalil S, Maurer M. Comparison of Urticaria Activity Score over 7 days (UAS7) values obtained from once-daily and twice daily versions: results from the ASSURE-CSU study. Am J Clin Dermatol. 2018 Apr;19(2):267-74. doi: 10.1007/s40257-017-0331-8

Grange F, Mohr P, Harries M, Ehness R, Benjamin L, Siakpere O, Barth J, Stapelkamp C, Pfersch S, McLeod LD, Kaye JA, Wolowacz S, Kontoudis I. Economic burden of advanced melanoma in France, Germany, and the UK: a retrospective observational study (Melanoma Burden-of-Illness Study). Melanoma Res. 2017 Dec;27(6):607-18. doi: 10.1097/CMR.0000000000000372

Kuznik A, Bego-Le-Bagousse G, Eckert L, Gadkari A, Simpson E, Graham CN, Miles L, Mastey V, Mahajan P, Sullivan SD. Economic evaluation of dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults. Dermatol Ther. 2017 Dec;7(4):493-505. doi: 10.1007/s13555-017-0201-6

Maurer M, Abuzakouk M, Berard F, Canonica W, Oude Elberink H, Gimenez-Arnau A, Grattan C, Hollis K, Knulst A, Lacour JP, Lynde C, Marsland A, Mcbride D, Nakonechna A, Ortiz De Frutos J, Proctor C, Sussman G, Sweeney C, Tian H, Weller K, Wolin D, Balp M-M. The burden of chronic spontaneous urticaria is substantial: real-world evidence from ASSURE-CSU. Allergy. 2017 Dec;27(12):2005-16. doi: 10.1111/all.13209

Warren R, Halliday A, Graham CN, Gilloteau I, Miles L, Sherif B, Mcbride D. Secukinumab significantly reduces work impairment and indirect costs compared to ustekinumab and etanercept in the United Kingdom. Poster presented at the 2017 ISPOR 20th Annual European Congress; November 8, 2017. Glasgow, Scotland.

Yosipovitch G, Reaney M, Eckert L, Nelson L, Clark M, Ardeleanu M, Radin A, Gadkari A. Validation of the peak pruritus numerical rating scale: results from clinical studies of dupilumab in adult patients with moderate-to-severe atopic dermatitis. Poster presented at the 9th World Congress on Itch; October 2017. Wroclaw, Poland.

Maurer M, Houghton K, Guillet G, Kasujee I, Labrador M, Marsland A, Mcbride D, Rossi O, Stull DE, Valesco M, Chapman-Rothe N. Quality of life and presence of angioedema among patients with chronic urticaria in Europe: longitudinal findings from the worldwide prospective observational AWARE study. Presented at the 26th EADV Congress; September 16, 2017. Geneva, Switzerland.

Strober B, Zhao Y, Herrera V, Wolin D, McLeod L, Eid D, Bello T. Secukinumab provides greater symptom control in psoriasis-related pain, itching, and scaling compared with previous treatments: evidence from a real-world study in the US. Poster presented at the 26th EADV Congress; September 13, 2017. Geneva, Switzerland.

Strober B, Zhao Y, Herrera V, Wolin D, McLeod L, Davenport E, Bello T. Secukinumab patients achieve high overall treatment satisfaction and psoriasis-related and symptom improvement in a real world setting. Presented at the 26th EADV Congress; September 13, 2017. Geneva, Switzerland.

Maurer M, Houghton K, Guillet G, Kasujee I, Labrador M, Marsland M, Mcbride D, Rossi O, Stull DE, Valesco M, Chapman-Rothe N. Quality of life and disease control among patients with chronic urticaria in Europe: longitudinal findings from the worldwide prospective observational AWARE study. Poster presented at the 26th EADV Congress; September 13, 2017. Geneva, Switzerland.

Weatherall M, Aantaa R, Conti G, Garratt CJ, Pohjanjousi P, Lewis MA, Moore N, Perez-Gutthann S. A multinational, drug utilisation study to investigate the use of dexmedetomidine (Dexdor®) in clinical practice in the EU. Br J Clin Pharmacol. 2017 Sep;83(9):2066-76. doi: 10.1111/bcp.13293

Carman WJ, Accortt NA, Anthony MS, Iles J, Enger C. Pregnancy and infant outcomes including major congenital malformations among women with chronic inflammatory arthritis or psoriasis, with and without etanercept use. Pharmacoepidemiol Drug Saf. 2017 Sep;26(9):1109-18. doi: 10.1002/pds.4261

Anthony M, Calingaert B, McQuay LJ, Andrews E, McGrath L, Rothman KJ, Rivero-Ferrer E. Suicide, suicidal behavior, and mortality rates in patients with psoriasis in England. Presented at the 33rd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 30, 2017. Montreal, Canada. [abstract] Pharmacoepidemiol Drug Saf. 2017 Aug; 26(Suppl 2):475. doi: 10.1002/pds